drugset / Trial / NCT02884479
An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
Phase 1/2
Unknown
75 enrolled
SciClone Pharmaceuticals International (Cayman) Development Limited
National Cheng-Kung University Hospital · collabParexel · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test PT-112 in Combination with Docetaxel in Subjects with Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects with Non-Small Cell Lung Cancer.
Timeline
- Start
- 2016-08
- Primary completion
- 2018-12
- Completion
- 2019-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMIFOPLATIN | Other / unclassified | — | Intravenous |
| Background | Docetaxel | Small molecule | 60 mg/m2 | — |